07:37 AM EDT, 09/12/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that Health Canada has approved Keytruda as a treatment for adults and children with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.

The approval is based on the results of phase 2 trials, including data from 504 patients across more than 30 cancer types, the company said.

Price: 114.80, Change: +0.09, Percent Change: +0.08